TrialBMC medicine2026

The tumour microenvironment influences long-term tamoxifen benefit in postmenopausal ER+/HER2- breast cancer patients: a secondary analysis of the randomised Stockholm Tamoxifen (STO-3) trial.

Paula Camargo-Romera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.